|
gptkbp:instance_of
|
gptkb:pharmaceuticals
|
|
gptkbp:approves
|
gptkb:European_Union
gptkb:United_States
|
|
gptkbp:atccode
|
J05 AX14
|
|
gptkbp:available_on
|
generic version
|
|
gptkbp:can_be_combined_with
|
gptkb:glecaprevir
|
|
gptkbp:casnumber
|
1256580-50-0
|
|
gptkbp:chemical_formula
|
C20 H24 N4 O4 S
|
|
gptkbp:clinical_trial
|
Phase 3
global sites
successful in achieving SVR
|
|
gptkbp:clinical_use
|
in combination with glecaprevir
|
|
gptkbp:contraindication
|
severe hepatic impairment
certain antiepileptics
|
|
gptkbp:developed_by
|
gptkb:Abb_Vie
|
|
gptkbp:dosage_form
|
oral tablet
|
|
gptkbp:drug_interactions
|
minimal with other drugs
|
|
gptkbp:duration
|
8 to 12 weeks
|
|
gptkbp:effective_date
|
2017-11-24
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Pibrentasvir
|
|
gptkbp:indication
|
chronic hepatitis C virus infection
|
|
gptkbp:invention
|
patented
|
|
gptkbp:is_effective_against
|
over 95% cure rate
|
|
gptkbp:lifespan
|
approximately 12 hours
|
|
gptkbp:manufacturer
|
gptkb:Abb_Vie_Inc.
|
|
gptkbp:marketed_as
|
gptkb:Mavyret
|
|
gptkbp:mechanism_of_action
|
NS5 A inhibitor
|
|
gptkbp:patient_population
|
adults and children over 12 years
|
|
gptkbp:pharmacokinetics
|
high bioavailability
inhibits HCV replication
|
|
gptkbp:provides_guidance_on
|
recommended by WHO
|
|
gptkbp:research_focus
|
HCV genotype 1-6
|
|
gptkbp:route_of_administration
|
oral
|
|
gptkbp:safety_features
|
generally well tolerated
|
|
gptkbp:safety_measures
|
required during treatment
|
|
gptkbp:service_frequency
|
once daily
|
|
gptkbp:side_effect
|
fatigue
headache
nausea
diarrhea
insomnia
liver enzyme elevations
|
|
gptkbp:storage
|
room temperature
|
|
gptkbp:trade
|
gptkb:Mavyret
|
|
gptkbp:treatment
|
with ribavirin
sustained virologic response (SVR)
|
|
gptkbp:type_of_care
|
important for treatment success
|
|
gptkbp:used_for
|
treatment of hepatitis C
|
|
gptkbp:weight
|
396.49 g/mol
|
|
gptkbp:bfsParent
|
gptkb:Mavyret
|
|
gptkbp:bfsLayer
|
6
|